# US 2006/0154916 A1 · Condensed azepines as vasopressin agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154916 A1
- Document ID: US20060154916A1
- Status: Published application
- Kind: A1
- Application number: 11/370,861
- Filed: 2006-03-09
- Published: 2006-07-13
- Earliest claimed: 2000-01-05
- Assignees: Ferring B.V.
- Inventors: Doreen Ashworth; Gary Pitt; Peter Hudson; Christopher Yea; Richard Franklin
- Web page: https://patentgrep.com/patent/US20060154916A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61P 5/10: of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

## Claims

### Claim 1

A compound according to general formula 1, or a pharmaceutically acceptable salt thereof,
wherein
A is a bicyclic or tricyclic azepine derivative selected from general formulae 2 to 7
A1, A4, A7 and A10 are each independently selected from CH2, O and NR8;
A2, A3, A9, A11, A13, A14 and A15 are each independently selected from CH and N;
either A5 is a covalent bond and A6 is S, or A5 is N═CH and A6 is a covalent bond;
A8 and A12 are each independently selected from NH and S;
A18 and A17 are both CH2, or one of A16 and A17 is CH2 and the other is selected from CH(OH), CF2, O, Sox, and NR8,
V1 and V2 are both H, OMe or F, or one of V1 and V2 is OH, OMe, OBn, OPh, O-acyl, Br, CI, F, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —S(CH2)pS— or —O(CH2)pO—;
W1 is either O or S;
X1 and X2 are both H, or together are ═O or ═S;
Y is OR5 or NR6R7;
Z is S or —CH═CH—;
R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, CI and Br;
R5 is slected from H and lower alkyl;
R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n-;
R8 is H or lower alkyl;
N=3, 4, 5 or 6;
P=2 or 3;
and x is 0, 1 or 2.

### Claim 2 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 2.

### Claim 3 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 3.

### Claim 4 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 4.

### Claim 5 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 5.

### Claim 6 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 6.

### Claim 7 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 7.

### Claim 8 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A is a group according to general formula 7, Z is -Ch=Ch- and both A16 and A17 are —CH2.

### Claim 9 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein one of R1 and R2 is CI or Me and the other is H, and both R3 and R4 are H.

### Claim 10 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein one of V1 and V2 is OMe or OBn and the other is H.

### Claim 11 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X1 and X2 together are ═O and Y is NR6R7.

### Claim 12 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is
wherein
W1 is either O or S;
one of Ra and Rb is CI or methyl and the other is H;
Rc is methyl or benzyl; and
R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n-; and
n is 3, 4, 5 or 6.

### Claim 13 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is
wherein
W1 is either O or S;
one of Ra and Rb is CI or methyl and the other is H;
Rc is methyl or benzyl; and
R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n-; and
n is 3, 4, 5 or 6.

### Claim 14 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein V1 and V2 are both H.

### Claim 15 (depends on 14)

A compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein X1 and X2 together are ═O and Y is NR6R7.

### Claim 16 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is
wherein
W1 is either O or S;
one of Ra and Rb is CI or methyl and the other is H;
R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n-; and
n is 3, 4, 5 or 6.

### Claim 17 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is
wherein
W1 is either O or S;
one of Ra and Rb is CI or methyl and the other is H;
R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n-; and
n is 3, 4, 5 or 6.

### Claim 18 (depends on 1)

A compound according to claim 1 which is selected from
1-(2methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-4-hydroxy-1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl) benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-1-(3-chloro-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-4-methoxy-L-proline-N,N-dimethylamide,
(4R)-1-(2-chloro-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-4-methoxy-L-proline-N,N,dimethylamide,
(4R)-4-benzyloxy-1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-4-methoxy-1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-4-methoxy-1-(3-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-1-(2-chloro-4-(5,6,7,8-tetrahydro-1-benzazepin-1-ylcarbonyl)benzyl-carbamoyl)-L-proline-N,N-dimethylamide,
(4R)-1-(4-(10,11-dihydro-5H-pyrrolo[2,1-c](1,4)benzodiazepine-10-yl.carbonyl)-2-methylbenzylcarbamoyl)-4methoxy-L-proline-N,N-dimethylamide,
(4R)-1-)-2-chloro-4-(10,11-Dihydro-5H-pyrrolo [2,1-c](1,4)benzodiazepine-10-ylcarbonyl)benzylcarbamoyl)-4-methoxy-L-proline-N,N-dimethylamide, and
(4R)-1-(4-(10,11-dihydro-5H-pyrrolo[2,1-c](1,4)benzodiazepine-10-ylcarbonyl)-2-methylbenzylcarbamoyl)-4-methoxy-L-proline-N,N-dimethylthioamide
or a pharmaceutically acceptable salt thereof.

### Claim at position 19

-20. (canceled)

### Claim 21 (depends on 1)

A pharmaceutical composition which contains active agent selected from compounds and pharmaceutically acceptable salts according to claim 1.

### Claim 22 (depends on 21)

A method for the treatment of polyuria, which method comprises the administration to a person in need of such treatment of an effective amount of the composition according to claim 21.

### Claim at position 22

-25. (canceled)

### Claim 26 (depends on 21)

A method of treatment of nocturnal enuresis, nocturia and central diabetes insipidus, which method comprises the administration to a person in need of such treatment of an effective amount of a composition according to claim 21.

### Claim 27 (depends on 21)

A method for the control of urinary incontinence, which method comprises the administration to a person in need of such treatment of an effective amount of a composition according to claim 21.

### Claim 28 (depends on 27)

A method of treatment according to claim 27, wherein the treatment results in voiding postponement.

### Claim 29 (depends on 21)

A method of treatment of bleeding disorders, which method comprises the administration to a person in need of such treatment of an effective amount of a composition according to claim 21.
